Malvern-based TELA Bio, Inc. announced its new CEO and director would be Heather Getz.
The commercial-stage medical technology company focusing on soft-tissue reconstruction solutions said Getz will assume the position and replace Antony Koblish, one of TELA Bio’s co-founders. Getz’s new role was effective August 4.
“As TELA Bio enters its next phase of growth and commercial execution, the Board is pleased to welcome Heather as our next Chief Executive Officer,” Joseph Capper, chairman of the Board of TELA Bio, said. “Heather brings a proven track record of driving operational excellence, leading organizations through complex business and financial transformations, and creating long-term value. We are confident that under Heather’s leadership, TELA Bio will build on its strong foundation, expand its impact for patients and surgeons, and deliver value for our shareholders and employees.”
Previously, Getz served as the executive VP and CFO and COO of Butterfly Network, Inc., where she oversaw strategy, capital allocation, cash runway and investor relations. Prior to her tenure at Butterfly, Getz was executive VP and Chief Financial and Administrative Officer at BioTelemetry, Inc., prior to its acquisition by Philips Healthcare in 2021.
“I am honored to join TELA Bio at such an exciting time in the Company’s evolution,” Getz said. “TELA Bio has built a differentiated portfolio, a strong commercial foundation, and a clear commitment to improving outcomes for patients and surgeons. I am excited to partner with our talented employees, leadership team, customers, and Board to build on that momentum, accelerate commercial execution, strengthen customer relationships, and expand our impact. Together, we have a tremendous opportunity to advance the Company’s mission and create long-term value for all our stakeholders.”
The board also expressed its appreciation to Koblish for his commitment to the company.
“It has been a privilege to lead TELA Bio and work alongside such a talented and dedicated team,” Koblish said. “I am incredibly proud of what we have accomplished together over the years, building and commercializing an innovative portfolio of products supported by compelling clinical evidence. I am confident that Heather and the entire team will build on this foundation, and I look forward to watching TELA Bio continue advancing its mission and creating value for patients, surgeons, and shareholders.”